

Supplementary material

Development of green methods for the determination of elemental impurities in commercial pharmaceutical tablets

Vitoria H. Cauduro^a, Alessandra S. Henn^a, Rochele S. Picoloto^a, Edson I. Müller^a,

Marcia F. Mesko^b, Erico M. M. Flores^{a*}

^aDepartamento de Química, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil

^bCentro de Ciências Químicas, Farmacêuticas e de Alimentos, Universidade Federal de Pelotas, 96160-000, Capão do Leão, RS, Brazil

Contents

Figure S-1

Molecular structure of the APIs contained in the oral drugs used in this study: A) canagliflozin, B) glibenclamide, C) metformin hydrochlorate, D) pioglitazone hydrochloride, E) repaglinide, and F) sitagliptin phosphate.

Table S-1

Analyte recovery after oral drug samples digestion by MAWD and MAWD-UV using optimized conditions (values in percentage, mean \pm standard deviation, n = 3).




Figure S1. Molecular structure of the APIs contained in the oral drugs used in this study: A) canagliflozin, B) glibenclamide, C) metformin hydrochlorate, D) pioglitazone hydrochloride, E) repaglinide, F) sitagliptin phosphate.

Table S1. Analyte recovery after oral drug sample digestion by MAWD and MAWD-UV using optimized conditions (values in percentage, mean \pm standard deviation, n = 3).

Sample	Analyte						
	As	Cd	Co	Hg	Ni	Pb	V
<u>MAWD</u>							
CANA ^b	108 \pm 3	101 \pm 2	103 \pm 2	93.9 \pm 2.2	103 \pm 2	94.2 \pm 3.8	92.8 \pm 1.6
GLIB ^a	95.9 \pm 2.1	99.4 \pm 1.1	96.8 \pm 1.9	101 \pm 3	105 \pm 1	101 \pm 3	98.5 \pm 1.8
MET ^a	108 \pm 5	103 \pm 2	101 \pm 1	97.9 \pm 3.4	100 \pm 1	105 \pm 5	104 \pm 1
SITA ^a	93.7 \pm 3.6	90.2 \pm 1.2	97.9 \pm 0.9	96.6 \pm 1.3	99.9 \pm 0.7	90.5 \pm 0.7	102 \pm 3
PIO ^a	98.8 \pm 2.7	94.9 \pm 2.5	100 \pm 1	109 \pm 1	102 \pm 2	93.2 \pm 0.3	95.9 \pm 0.6
REPA ^a	97.5 \pm 0.7	90.1 \pm 1.9	95.5 \pm 4.2	102 \pm 2	98.9 \pm 1.0	97.0 \pm 2.9	95.4 \pm 1.9
<u>MAWD-UV</u>							
CANA	103 \pm 1	101 \pm 2	100 \pm 2	96.7 \pm 2.8	97.8 \pm 3.2	98.3 \pm 2.4	100 \pm 3
GLIB	110 \pm 1	97.6 \pm 1.0	95.8 \pm 1.2	107 \pm 3	106 \pm 4	94.7 \pm 2.0	105 \pm 1
MET	103 \pm 3	106 \pm 3	105 \pm 3	95.5 \pm 1.6	105 \pm 3	98.3 \pm 3	96.3 \pm 3.3
PIO	106 \pm 4	100 \pm 2	97.8 \pm 1.8	97.6 \pm 2.9	99.4 \pm 1.2	104 \pm 3	105 \pm 2
REPA	106 \pm 3	96.9 \pm 2.0	94.0 \pm 3.8	92.5 \pm 2.6	92.5 \pm 3.1	98.2 \pm 1.7	97.8 \pm 3.1
SITA	107 \pm 1	96.6 \pm 2.8	104 \pm 2	98.0 \pm 1.8	101 \pm 3	106 \pm 2	99.9 \pm 1.3

a: MAWD: 500 mg of sample, 2 mol L⁻¹ HNO₃, 1 mL of 50% H₂O₂ and irradiation program 1.

b: MAWD: 500 mg of sample, 3 mol L⁻¹ HNO₃, 1 mL of 50% H₂O₂ and irradiation program 2.